DISITBiotech

Executive Summary

DISITBiotech is a Spanish pre-clinical biotechnology company developing peptide-based therapies that inhibit the TGF-β pathway to address radiation-induced damage in oncology. Founded in 2019 and based in Barcelona, the company aims to improve quality of life and survival for cancer patients undergoing radiotherapy. Its proprietary platform targets a well-validated biological pathway, potentially reducing fibrosis and other radiation side effects. However, as a pre-clinical entity with no disclosed funding or partnerships, DISITBiotech faces significant development and commercialization risks. The company has not yet advanced to clinical trials, and its technology remains unvalidated in humans. Despite the promising therapeutic hypothesis, early-stage biotechs typically require substantial capital and time to reach key milestones. The lack of publicly available data on preclinical results or intellectual property further limits assessment. Nonetheless, if successful, DISITBiotech's approach could address a significant unmet need in supportive oncology care.

Upcoming Catalysts (preview)

• Q3 2026IND/CTA submission for lead candidate20% success
• Q4 2026Release of preclinical efficacy data in radiation-induced fibrosis models40% success
• TBDSecuring seed or Series A financing30% success